Ectopic ACTH Syndrome and Hypothyroidism Due to Right Renal Small Round Blue Cell Tumor: A Case Report

Weipu Mao  
Southeast University Zhongda Hospital

Jiajia Xu  
Southeast University Zhongda Hospital

Haowen Lu  
Southeast University Zhongda Hospital

Yali Wang  
Southeast University Zhongda Hospital

Lihua Zhang  
Southeast University Zhongda Hospital

Chen Ming (✉ mingchenseu@126.com)  
Southeast University Zhongda Hospital  https://orcid.org/0000-0002-3572-6886

Case Report

Keywords: Renal small round blue cell tumor, Cushing syndrome, Hypothyroidism, EWSR1, Case report

DOI: https://doi.org/10.21203/rs.3.rs-71403/v1

License: © Chenshen@126.com This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Small round blue cell malignancies are rare and highly aggressive tumors that are commonly located in the soft tissues or axial bones of the bone or trunk and are particularly rare in the kidney. The common cause of ectopic ACTH syndrome is pulmonary neuroendocrine tumors, such as small cell carcinomas and carcinoid tumors. Here, we present an unusual case of ectopic ACTH syndrome and hypothyroidism caused by small round blue cell tumor of the right kidney.

**Case presentation:** A 19-year-old girl presented with a history of right lumbar pain and discomfort for 2 months, aggravated for 2 days. Abdominal contrast-enhanced computed tomography and computed tomography angiography showed right suprarenal pole occupancy with subepithelial hemorrhage. Preoperative hormone levels including plasma total cortisol (PTC), adrenocorticotropic hormone (ACTH) and thyroid hormone measurements were abnormal, indicating that the patient had Cushing syndrome and hypothyroidism. The patient underwent right radical nephrectomy. Histopathological analysis revealed a renal small round blue cell tumor (consistent with a primitive neuroectodermal tumor), with positive immunohistochemistry for CD99 and Ki67 (about 10%) and molecular pathology for EWSR1 gene fusions. PTC, ACTH and thyroid hormone returned to normal after surgery.

**Conclusions:** We report a rare ectopic ACTH syndrome and hypothyroidism due to renal small round blue cell tumor. The clinical manifestation of renal small round blue cell tumor is non-specific and the diagnosis relies on pathological morphology, immunohistochemistry and fusion gene detection. At present, surgery combined with radiotherapy and chemotherapy is used in the treatment, but the prognosis is still not optimistic.

**Background**

Small round blue cell tumors are a rare class of malignant tumors that can occur in all parts of the body, most commonly in bone or soft tissues in the trunk or axial bones, and rarely in the kidney(1, 2). Small round blue cell tumors are histologically characterized by proliferation of small round tumor cells with sparse cytoplasm, which are often difficult to distinguish by standard histology or immunohistochemistry(3, 4). The disease usually has an insidious onset, rapid progress, easy recurrence and metastasis, and poor prognosis. Patients with small round blue cell tumors require rapid treatment(5).

Cushing syndrome caused by excessive secretion of ACTH from tumor tissues other than the pituitary gland is called ectopic ACTH syndrome, accounting for 10%-20% of Cushing syndrome(6). The common causes of ectopic ACTH syndrome are lung or bronchial tumors, followed by thymic and pancreatic tumors(7). Herein, we introduce a rare case of ectopic Cushing syndrome and hypothyroidism caused by a malignant tumor of small round blue cell in the right kidney.

**Case Presentation**

A 19-year-old girl presented to our hospital with a history of right lumbar pain and discomfort for 2 months and aggravated for 2 days. The patient felt the right waist pain 2 months ago, which was persistent dull pain, and increased right-sided back pain after running 2 days ago. Abdominal computed tomography (CT) showed right renal hamartoma with hemorrhage in the local hospital. The patient had no significant medical history and was not receiving any medication at the time of referral. Of note in the history was that the patient discovered facial swelling, increased acne on the face and back, and scanty menstruation six months ago. Upon admission, physical examination revealed concentric obesity and positive percussion pain in the right costal hom.

**Laboratory Examination**

Blood routine (Sep 5): white-cell $17.15 \times 10^9$/L, neutrophil $16.01 \times 10^9$/L, neutrophil percentage 93.3%. Renal function (Sep 5): urea nitrogen 4.6 mmol/L, creatinine 52 umol/L. Liver function (Sep 5): total protein 60.5 g/L, albumin 34.5 g/L. Thyroid hormone (Sep 5): triiodothyronine 0.638 nmol/L, thyroxine 64.37 nmol/L, free triiodothyronine 1.62 pmol/L, free thyroxine 10.26 pmol/L, thyroid stimulating hormone 0.847 uIU/mL. Female hormones (Sep 6): dehydroepiandrosterone sulfate > 1000
ug/dL, sex hormone binding globulin 12.6 nmol/L, cortisol > 60 ug/dL. Cortisol rhythm (Sep 6): cortisol 82.255 ug/dL (8: am), cortisol 92.705 ug/dL (4: pm), cortisol 65.859 ug/dL (12: pm). Adrenocorticotrophic hormone (ACTH) rhythm (Sep 6): ACTH 231,756 pg/mL (8: am), ACTH 242.763 pg/mL (4: pm), ACTH 202.883 pg/mL (12: pm). (Table 1)
Table 1
Changes in patients’ laboratory examination results.

| Normal Ranges | Sep 5  | Sep 6  | Sep 7 (8:00 am) | Sep 8 (5:00 pm) | Sep 9  | Sep 10 | Sep 11 | Sep 21 |
|---------------|--------|--------|----------------|----------------|--------|--------|--------|--------|
| **Blood routine** |        |        |                |                |        |        |        |        |
| White-cell (10^9/L) | 3.5–9.5 | 17.15  | 24.1 | 19.87 | 26.74 | 11.36 | 8.89  | 6.69  | 7.41  |
| Red-cell (10^12/L) | 3.8–5.1 | 4.75  | 4.61 | 4.25  | 3.24  | 2.84  | 2.85  | 2.59  | 3.39  |
| Hemoglobin (g/L) | 115–150 | 145   | 143 | 130  | 98  | 86  | 85  | 78  | 101  |
| Platelets (10^9/L) | 125–350 | 197 | 168 | 106 | 137 | 90  | 67  | 58  | 262  |
| Neutrophil count (10^9/L) | 1.8–6.3 | 16.01 | 22.56 | 19.12 | 25.65 | 10.37 | 86.21 | 7.66  | 5.78  | 5.35  |
| Neutrophil percentage (%) | 40–75 | 93.3 | 93.61 | 96.24 | 95.9 | 91.31 | 86.21 | 86.5 | 72.11  |
| **Renal function** |        |        |                |                |        |        |        |        |
| Urea nitrogen (mmol/L) | 2.9–7.2 | 4.6 | 7.6 | 9.9 | 10.6 | 11.3 | 8.9 | 7.2 | 8.2  |
| Creatinine (umol/L) | 53–132 | 52 | 117 | 124 | 146 | 155 | 137 | 116 | 112  |
| Uric acid (umol/L) | 150–360 | 180 | 223 | 239 | 321 | 378 | 296 | 312 | 393  |
| **Liver function** |        |        |                |                |        |        |        |        |
| Total protein (g/L) | 66.0–83.0 | 60.5 | 56.2 | 55.2 | 36.2 | 42.3 | 45.8 | 50.2 | 73.9  |
| Albumin (g/L) | 40.0–55.0 | 34.5 | 36.8 | 33.8 | 24.3 | 30.3 | 33 | 34.4 | 47.1  |
| Globulin (g/L) | 20.0–40.0 | 26 | 19.4 | 21.4 | 11.9 | 12 | 22.8 | 15.8 | 26.8  |
| **Thyroid Hormone** |       |        |                |                |        |        |        |        |
| Triiodothyronine (nmol/L) | 1.23–3.08 | 0.638 |        |        |        |        |        |        | 0.582 | 1.365 |
| Thyroxine (nmol/L) | 65.64–181.47 | 64.37 |        |        |        |        |        |        | 78.99 | 94.287 |
| Free triiodothyronine (pmol/L) | 2.77–7.08 | 1.62 |        |        |        |        |        |        | 1.86 | 4.35 |
| Free thyroxine (pmol/L) | 11.97–21.88 | 10.26 |        |        |        |        |        |        | 14.84 | 18.14 |
| Thyroid stimulating hormone (uIU/mL) | 0.27–4.2 | 0.847 |        |        |        |        |        |        | 3.9 | 2.26 |
| **Female hormones** |        |        |                |                |        |        |        |        |
| Follicle stimulating hormone (mIU/mL) | 4.6–8.6 | 4.77 |        |        |        |        |        |        | 6.96 |

Page 4/12
|            | Normal Ranges | Sep 5 | Sep 6 | Sep 7 | Sep 8 (8:00 am) | Sep 8 (5:00 pm) | Sep 9 | Sep 10 | Sep 11 | Sep 21 |
|------------|---------------|-------|-------|-------|----------------|-----------------|-------|--------|--------|--------|
| Luteinizing hormone (IU/L) | 1.5-7.0       | 3.75  |       |       |                |                 |       |        |        | 7.64   |
| Estradiol (pg/mL)         | 18–63         | 47    |       |       |                |                 |       |        |        | 34     |
| Testosterone (ng/mL)      | 0.15–0.51     | 2.13  |       |       |                |                 |       |        |        | 0.24   |
| Prolactin (ng/mL)         | 3.5–24.2      | 15.72 |       |       |                |                 |       |        |        | 16.69  |
| Dehydroepiandrosterone sulfate (ug/dL) | 51–321        | >1000 |       |       |                |                 |       |        |        | 167.2  |
| Sex hormone binding globulin (nmol/L) | 12.6          |       |       |       |                |                 |       | 49.2   |        |        |
| Cortisol (ug/dL)          | 8.7–22.4      | >60   |       |       |                |                 |       |        |        | 12.44  |
| **Cortisol rhythm**       |               |       |       |       |                |                 |       |        |        |        |
| Cortisol (8:am) (ug/dL)   | 4.26–24.85    | 82.255|       |       | 11.495         | 17.762          |       |        |        |        |
| Cortisol (4:pm) (ug/dL)   | 1.9–17.3      | 92.705|       |       | 5.847          | 6.107           |       |        |        |        |
| Cortisol (12:pm) (ug/dL)  | 65.859        | 6.088 |       |       | 2.921          |                 |       |        |        |        |
| **ACTH rhythm**           |               |       |       |       |                |                 |       |        |        |        |
| ACTH (8:am) (pg/mL)       | 7.2–63.3      | 231.756|       |       | 36.489         | 34.742          |       |        |        |        |
| ACTH (4:pm) (pg/mL)       | 3.6–31.7      | 242.763|       |       | 30.08          | 25.388          |       |        |        |        |
| ACTH (12:pm) (pg/mL)      | 202.883       | 22.947|       |       | 35.454         |                 |       |        |        |        |

**Imaging Examinations**

Abdominal imaging with contrast-enhanced computed tomography and computed tomography angiography (Sep 5) showed right suprarenal pole occupancy (size 9.4cm*9.9 cm) with subepithelial hemorrhage, right renal artery branch supplied blood, and the right portal lymph node enlargement (Fig. 1).

**Treatment**

Re-examination of the patient's blood routine, renal function and protein level showed that the infection index further increased, and the renal function and protein level decreased. The patient received double J tube implantation under left ureteroscope plus right radical nephrectomy plus clearance of right perirenal hematoma plus lysis of right perirenal adhesion on Sep 8. The patients were transferred to ICU monitoring and treatment after surgery.

**Pathology**
The maximum diameter of the tumor was 8 cm. The tumor involved renal parenchyma, perirenal adipose tissue and adrenal gland, and a carcinoma thrombus was seen in the vasculature. Under light microscope, the tumor cells were lamellar, composed of a large number of small round cells with relatively uniform morphology and little cytoplasm (Fig. 2). The immunohistochemical results were positive for CD99 and Ki67 (about 10%), while Vim, Syn, FSH and ACTH were negative (Fig. 3). EWSRI gene fusion was detected by fluorescence in situ hybridization (FISH) (Fig. 4). According to the results of postoperative pathology and molecular pathological examination, the finally diagnosed was renal small round blue cell tumor (consistent with primitive neuroectodermal tumor (PNET)).

**Follow-up**

The blood routine, renal function and protein levels of the patients showed a trend of improvement for three consecutive days after surgery, ACTH and plasma total cortisol (PTC) decreased to normal, and thyroid hormones tended to normal (Table 1). The patient's facial swelling was reduced and the acne on her face and back subsided. However, three weeks after surgery, the patient died while preparing for further chemotherapy.

**Discussion And Conclusions**

PNET is a highly malignant small round blue cell tumor with neural differentiation. According to the location, PNET can be divided into central PNET (cPNET) and peripheral PNET (pPNET)(8). PNET usually occurs in children and adolescents, and the most common site is bone or soft tissue in the trunk or axial bone. PNET in the genitourinary system is relatively rare, and even rarer in the kidney(9). Renal PNET is a type of pPNET with a median age of about 27 years old, and is slightly more common in males(10).

The clinical manifestations of renal PNET are non-specific. The gross section of tumor tissue was gray, grayish brown and tender, accompanied by hemorrhage, necrosis and cystic degeneration. In the histological examination of renal PNET, the tumor cells were arranged in nest shape, and Homer-Wright rosettes were seen. Homer-Wright rosettes are one of the main histological bases for the diagnosis of renal PNET(11). The diagnosis of renal PNET mainly depends on pathological examination. With the improvement of immunohistochemical techniques, immunohistochemistry has become an important basis for pathological diagnosis of renal PNET(12). CD99 is a monoclonal antibody that recognizes p30/32 glycoprotein and can be detected in almost all renal PNET(13). In addition, some cases expressed vimentin, NSE, S-100 and Syn(14). There is no standardized criteria for the pathological diagnosis of renal PNET, which is generally considered to be consistent with(15): (1) Homer-Wright rosettes under light microscope; (2) positivity for CD99 and other neural markers (at least 2 kinds).

In recent years, it has been found that 90%-95% of PNET have a t(11; 22) (q24; q12) chromosome translocation, leading to the production of the EWS/FLI-1 fusion gene(16). It has been shown that the FISH method detects EWSR1 gene fusions with a sensitivity of 92.3% and a specificity of 100%(17). Therefore, the FISH method to detect fusion genes formed by PNET-specific chromosomal translocations has greater diagnostic and differential diagnostic value. In summary, the diagnosis of renal PNET should be comprehensively judged by light microscopic morphology, immunohistochemistry and FISH method. In the pathological diagnosis of this patient, immunohistochemistry showed CD99 and Ki67 positivity, FISH showed EWSR1 gene fusion, and the diagnosis of small round blue cell tumor was confirmed.

According to previous reports, ectopic ACTH syndrome is primarily associated with small cell or lung carcinoid carcinoma, and also be associated with mediastinum, pancreases, thymus, and pheochromocytoma(18–20). Neuroendocrine tumors rarely produce excessive ACTH and cause ectopic ACTH syndrome. To our knowledge, we describe the first case of ectopic ACTH syndrome and hypothyroidism caused by a renal small round blue cell tumor. Although our patient received radical nephrectomy treatment, postoperative ACTH and PTC decreased to normal, and thyroid hormones tended to normalize. The patient's facial swelling was alleviated and the acne on the face and back subsided. However, due to the highly malignant and aggressive nature of the tumor, the patient died in preparation for further chemotherapy.
Renal PNET is more prone to recurrence and metastasis than other renal tumors, with the most common site of metastasis being the lung, followed by the liver and bone. 1/3 of patients have a renal vein or inferior vena cava thrombus at the time of diagnosis, which makes treatment often ineffective. The prognosis of renal PNET is generally poor, with a 5-year overall survival rate of approximately 45–55%. Due to the rarity of renal PNET, there is no uniform standard of treatment for renal PNET. Renal PNET is still a rare tumor, and more cases need to be accumulated to explore better treatment options.

**Abbreviations**

PNET, Primitive neuroectodermal tumor, PTC, Plasma total cortisol, ACTH, Adrenocorticotrophic hormone, CT, Computed tomography.

**Declarations**

**Ethics Approval and Consent to Participate** The study was in line with the Helsinki Declaration and approved by the Ethics Committee at the Affiliated Zhongda Hospital of Southeast University. The study outcomes will not affect the future management of the patients. The use of human blood samples was in accordance with the legislation in China. Informed consent was obtained from the controls and patients or their relatives.

**Consent for publication** Written consent was obtained from the patient to publish this case report.

**Availability of data and materials** The dataset used during the study are available from the corresponding author on a reasonable request.

**Conflicts of Interest** We declare that there are no conflicts of interest between authors.

**Funding** This work was supported by the National Natural Science Foundation of China (No. 81572517 and 81872089), Natural Science Foundation of Jiangsu Province (BK20161434), Jiangsu Provincial Medical Innovation Team (CXTDA2017025), and Jiangsu Provincial Medical Talent (ZDRCA2016080).

**Authors’ contributions** WM, LZ and MC designed the research. WM, JX and YW performed the research and analyzed results. WM, JX and HL wrote the paper. WM, LZ and MC edited the manuscript and provided critical comments. All authors read and approved the final manuscript.

**Acknowledgment** The authors are grateful for the invaluable support and useful discussions with other members of the urology department.

**References**

1. Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. J Pathol. 2018;245(1):29–40.
2. Gupta S, Billadello L, Casalino DD. Renal primitive neuroectodermal tumor. J Urol. 2012;187(6):2211–2.
3. Shibui Y, Miyoshi K, Kohashi K, Kinoshita Y, Kuda M, Yamamoto H, et al. Glypican-3 expression in malignant small round cell tumors. Oncol Lett. 2019;17(3):3523–8.
4. Cohn SL. Diagnosis and classification of the small round-cell tumors of childhood. Am J Pathol. 1999;155(1):11–5.
5. Hamidi N, Esen B, Kivrak H, Sertcelik A, Gulpinar O. A large and metastatic primitive neuroectodermal tumor of the kidney. Turk J Urol. 2015;41(3):152–4.
6. Terzolo M, Reimondo G, Ali A, Bovio S, Daffara F, Paccotti P, et al. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol. 2001;12(Suppl 2):83-7.
7. Comi RJ, Gorden P. Long-term medical treatment of ectopic ACTH syndrome. South Med J. 1998;91(11):1014–8.
8. Batsakis JG, Elnaggar AKJaiAP. Ewing’s Sarcoma and Primitive Neuroectodermal Tumors: Cytogenetic Cynosures Seeking a Common Histogenesis. 1997;4(4):207–20.
9. Mohsin R, Hashmi A, Mubarak M, Sultan G, Shehzad A, Qayum A, et al. Primitive neuroectodermal tumor/Ewing's sarcoma in adult uro-oncology: A case series from a developing country. Urol Ann. 2011;3(2):103–7.

10. Aghili M, Rafiei E, Mojahed M, Zare MJRT. Renal primitive neuroectodermal tumor: does age at diagnosis impact outcomes? 2012;4(1):15.

11. Song HC, Sun N, Zhang WP, Huang CR. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the urogenital tract in children. Chin Med J (Engl). 2012;125(5):932–6.

12. Patnaik N, Mishra K, Saini P, Agarwal N. Primitive neuroectodermal tumor of the kidney in a young male: Case report and review of literature. Urol Ann. 2015;7(2):236–9.

13. Nerli RB, Hiremath MB, Prabha V, Malpr P, Borges AJRIS. Technology. Primitive Neuroectodermal Tumor (PNET) of the Kidney with Level IV Inferior Vena Caval Thrombus: A Case Report. 2010;2(6):38–41.

14. Karpate A, Menon S, Basak R, Yuvaraja TB, Tongaonkar HB, Desai SB. Ewing sarcoma/primitive neuroectodermal tumor of the kidney: clinicopathologic analysis of 34 cases. Ann Diagn Pathol. 2012;16(4):267–74.

15. Folpe AL, Hill CE, Parham DM, O'Shea PA, Weiss SW. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000;24(12):1657–62.

16. Wu Y, Zhu Y, Chen H, Huang Y, Wei Q, Chen H, et al. Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib. 2010;123(15):2155–8.

17. Rekhi B, Vogel U, Basak R, Desai SB, Jambhekar NAJP, Research O. Clinicopathological and Molecular Spectrum of Ewing Sarcomas/PNETs, Including Validation of EWSR1 Rearrangement by Conventional and Array FISH Technique in Certain Cases. 2014.

18. Cieszyński Ł, Obolerńczyk MB, Szulc M, Sworczak KJEP. Cushing's syndrome due to ectopic ACTH secretion. 2016;67(4):458.

19. Levine AC, Sanchez JJEP. COMMENTARY ON CUSHING SYNDROME DUE TO ECTOPIC ACTH. 2017;23(8):1022–3.

20. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley R, Nieman LKJTJoCE, et al. Cushing's Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years’ Experience at the National. Institutes of Health. 2005;90(8):4955–62.

21. Hakky TS, Gonzalvo AA, Lockhart JL, Rodriguez AR. Primary Ewing sarcoma of the kidney: a symptomatic presentation and review of the literature. Ther Adv Urol. 2013;5(3):153–9.

Figures
Figure 1

Abdominal imaging with contrast-enhanced computed tomography and computed tomography angiography images. A and B, Computed tomography angiography images; C-F, Abdominal imaging with contrast-enhanced computed tomography images.
Figure 2

HE staining of tumor tissue.
Figure 3

Immunohistochemical results in tumor tissue. A, CD99; B, Ki67; C, Vim; D, Syn; E, FSH; F, ACTH.
Figure 4

EWSRI gene fusion was detected by fluorescence in situ hybridization (FISH).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CAREchecklistEnglish2013.pdf